SGLT2 inhibitors in acute myocardial infarction: what can we learn from the DAPA-MI trial? More news from American Heart Association Scientific Meeting

Eur Heart J Cardiovasc Pharmacother. 2024 Feb 23;10(2):95-97. doi: 10.1093/ehjcvp/pvad099.

Authors

Eri Toda Kato¹, Koh Ono², Basil S Lewis³

Affiliations

¹ D epartment of Cardiovascular Medicine and Department of Clinical Laboratory Department, Kyoto University Hospital, Kyoto, Japan.
² Department of Cardiovascular Medicine, Kyoto University Hospital, Kyoto, Japan.
³ Ruth and Bruce Rappaport School of Medicine of the Technion, Israel Institute of Technology, 3525433 Haifa, Israel.

PMID: 38061802
DOI: 10.1093/ehjcvp/pvad099

No abstract available

MeSH terms

American Heart Association
Humans
Myocardial Infarction* / diagnosis
Myocardial Infarction* / drug therapy
Sodium-Glucose Transporter 2 Inhibitors* / adverse effects
United States / epidemiology

Substances

Sodium-Glucose Transporter 2 Inhibitors